BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, December 24, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 27, 2021

View Archived Issues

Tetracyclines may help in mitochondrial disease

Read More

BioVaxys announces advances in its vaccine platforms

Read More

TLR2/6 activation using INNA-051 shows promise as prophylactic strategy against COVID-19

Read More

Model reveals key role of LGI1-ADAM22-MAGUK complex in transsynaptic nanoarchitecture

Read More

Enrollment begins in first-in-human trial of BI-1808 in solid tumors and CTCL

Read More

Vir releases initial phase I data for its HBV-neutralizing monoclonal antibody, VIR-3434

Read More

Keytruda approved in Europe as first-line treatment of metastatic MSI-H or dMMR colorectal cancer

Read More

First patients dosed in phase II study of GS-248 in systemic sclerosis

Read More

Incyte divulges FGFR-3 inhibitors

Read More

Medshine Discovery patents new PORCN inhibitors

Read More

Positive interim data from phase III prevention trial of REGEN-COV

Read More

Boragen presents new tyrosine kinase inhibitors

Read More

Qilu Regor Therapeutics patent details MAP4K1 inhibitors

Read More

New CDK inhibitors patented by Nuvation Bio

Read More

Microbial tyrosine metabolism protects against asthma

Read More

BLAZE-1 study of bamlanivimab plus etesevimab meets primary endpoint in high-risk COVID-19

Read More

OS Therapies receives approval for its phase IIb study of OST-HER2 in osteosarcoma

Read More

PARP inhibitor stenoparib shows activity against SARS-CoV-2

Read More

Rhythm presents positive clinical data and development update for setmelanotide

Read More

FDA approves phase II/III HIBISCUS trial of traumakine in patients with COVID-19

Read More

FDA allows Cardif Oncology to proceed with phase II trial of onvansertib in PDAC

Read More

Sorrento reports preliminary phase Ib results on COVI-MSC for COVID-19

Read More

Primary endpoint met in ACTIVATE-T trial of mitapivat in transfused patients with PK deficiency

Read More

Syndesi reports phase I data on SV2A modulator SDI-118

Read More

DPP-4 inhibitor sitagliptin prevents incidence of GvHD after allogeneic HSCT in AML

Read More

BriaCell reports data from monotherapy and combination therapy studies of Bria-IMT

Read More

FDA clears IND for anti-4-1BB therapeutic monoclonal antibody EU-101

Read More

NIAID reports phase IIb results on VRC-01 for HIV prevention

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 23, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing